Skip to content

26 October 2021

From the heart: Pandemic no barrier for medtech’s ASX listing

From the heart: Pandemic no barrier for medtech’s ASX listing

Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack. Globally, we will change how the world sees coronary artery disease.

Click here to read the article in the Sydney Morning Herald